Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Treasury Shares (2016 - 2025)

United Therapeutics (UTHR) has disclosed Treasury Shares for 17 consecutive years, with $4.3 billion as the latest value for Q4 2025.

  • Quarterly Treasury Shares rose 22.62% to $4.3 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.3 billion through Dec 2025, up 22.62% year-over-year, with the annual reading at $4.3 billion for FY2025, 22.62% up from the prior year.
  • Treasury Shares hit $32.8 million in Q4 2025 for United Therapeutics, up from $1.4 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $4.3 billion in Q3 2025 to a low of $2.6 billion in Q1 2021.
  • Historically, Treasury Shares has averaged $15.9 million across 5 years, with a median of $26.6 million in 2021.
  • Biggest five-year swings in Treasury Shares: changed 0.0% in 2021 and later surged 34.74% in 2024.
  • Year by year, Treasury Shares stood at $2.6 billion in 2021, then changed by 0.0% to $2.6 billion in 2022, then changed by 0.0% to $2.6 billion in 2023, then skyrocketed by 34.71% to $3.5 billion in 2024, then grew by 22.62% to $4.3 billion in 2025.
  • Business Quant data shows Treasury Shares for UTHR at $4.3 billion in Q4 2025, $4.3 billion in Q3 2025, and $3.5 billion in Q2 2025.